Timing and outcomes of second-line therapy in the era of daratumumab-based frontline therapy in AL amyloidosis.
Abdul-Hamid BazarbachiDivaya BhutaniJai RadhakrishnanMarkus MaparaMathew S MaurerSuzanne LentzschRajshekhar ChakrabortyPublished in: American journal of hematology (2024)